This renewal application requests funding for the continuation of the Southwest Oncology Group Clinical Trials Cooperative Grant at City of Hope (COH) for years 23-28. The COH faculty has a longstanding commitment to the Southwest Oncology Group as demonstrated by their leadership in the group, involvement in protocol development, meeting attendance, and enrollment of patients on SWOG studies. Dr. Steven Forman has chaired the BMT Committee since 1993 and pilot studies first tested at City of Hope have been incorporated into treatment arms on SWOG trials. Many of our faculty are Principal Investigators on SWOG trials and our annual enrollment to SWOG studies exceeds 100 patients per year. Our faculty involvement spans many disciplines including Medical Oncology, General Surgical Oncology, Urology, Pathology, Pharmacy and Pharmacology who serve on critical committees and enroll patients on clinical trials. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. Substantive scientific patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Our faculty have authored numerous publications. Clinical research through the Southwest Oncology Group continues to be an important part of the COH research portfolio. Recognizing the importance of SWOG to the institution, City of Hope supports the regulatory, data collection, and quality assurance infrastructure that is not entirely supported by the current grant. We anticipate that our participation in SWOG will continue to grow as our institution expands both on the main Duarte campus and with our burgeoning affiliate program.

Public Health Relevance

City of Hope recognizes the improved quality of patient care that is associated with participation in clinical trials. The institution is committed to enrolling our diverse population of patients on SWOG clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046368-26
Application #
8413454
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1988-01-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
26
Fiscal Year
2013
Total Cost
$340,319
Indirect Cost
$139,826
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2016) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol :
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 142 publications